NFL BIOSCIENCES : Adelivery agreement of his patent to United States
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announcement that the United States Patent and Trademark Office (USPTO) has issued on September 21 ons the number US 11123395, the patent portant on NFL-101, botanical drug candidate composed of natural proteins extracted from tobacco leaves, devoid of nicotine, and primarily destined at smoking cessation. This patent protects theinnovation on which NFL-101 is based until 2036 in the USA.
NFL Biosciences has adopted a knowledge management and protection strategy that has led it to file two families of patents giving it the exclusivity of its drug candidate NFL-101. This product patent, initially filed in France and approved in 2016, relates to an “aqueous extract of tobacco leaf and its use for the treatment of addiction”. The innovation on which NFL-101 is based is thus protected until 2036 in France and now in the United States. National registration applications are also under consideration in the following regions and countries: China, Japan, Canada, South Korea, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, Emirates United Arabs, Nigeria.
« Having a product patent gives us a protection strong to roll out our strategy over the next few years. This patent reinforces the protection of the innovation on which is based our drug candidate NFL-101 in the USA, a country that is part of the markets keys ciblIt’ss in the global approach deployed by NFL Biosciences. He was very important for us to have solid intellectual property in this high potential market : ithere are more than 30 million smokerss in the United States and 70 % of them say they want to quit »Declared Bruno Lafont, Deputy CEO and co-founder of NFL Biosciences.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier region whose most advanced botanical drug candidate is a smoking cessation aid. Called NFL-101, this natural product, extracted from standardized tobacco leaves and devoid of nicotine, is protected by two families of patents. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, long-term effective, short and personalized alternative.
Beyond NFL-101, NFL Biosciences has plans to develop botanical drugs for the treatment of cannabis use disorders and alcoholism.
NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). More information on www.nflbiosciences.com
Bruno Lafont – firstname.lastname@example.org – 04 11 93 76 67
Calyptus Agency – email@example.com – 01 53 65 68 68